|Bid||37.18 x 4000|
|Ask||37.19 x 1300|
|Day's Range||36.89 - 37.65|
|52 Week Range||29.99 - 43.08|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||21.77|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||1.56 (4.20%)|
|Ex-Dividend Date||Jan 28, 2021|
|1y Target Est||40.54|
The stay-at-home stocks quickly came back into favor on news of a setback with Johnson & Johnson's single-dose COVID-19 vaccine.
Michael Darda, Chief Economist & Macro Strategist at MKM Partners joins Yahoo Finance Live to discuss the outlook for economic recovery after U.S. regulators called for a pause in the use of Johnson & Johnson’s COVID-19 vaccine.
European Union countries will receive 50 million more coronavirus vaccines produced by Pfizer and BioNTech in the second quarter, the head of the EU Commission said on Wednesday, as deliveries expected at the end of the year will be brought forward. European Commission President Ursula von der Leyen said the earlier deliveries, which will start this month instead of in October, will take total supplies to the EU from Pfizer to 250 million doses in the second quarter in a move meant to compensate for lower supplies from AstraZeneca and possible problems with Johnson & Johnson. Von der Leyen confirmed the Commission was in talks with Pfizer and BioNTech for a new contract for 1.8 billion doses to be delivered in 2022 and 2023, confirming a Reuters report last week.